BeiGene, Ltd.

The momentum for this stock is not very good. BeiGene, Ltd. is not a good value stock. BeiGene, Ltd. is not very popular among insiders. BeiGene, Ltd. is a mediocre stock to choose.

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and c...

News

AbbVie slaps BeiGene with another blood cancer lawsuit, this time on BTK degrader trade secrets

FierceBiotech.com - Biotech AbbVie slaps BeiGene with another blood cancer lawsuit, this time on BTK degrader trade secrets\nfkansteiner\nWed, 09/11/2024 - 10:21...\n more…

BeiGene Announces Updates to Commercial Leadership Team

Business Wire BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. We are...\n more…

BeiGene shares new Tevimbra data at ESMO 2024

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

BeiGene Highlights TEVIMBRA Data in Lung and Gastrointestinal Cancers at ESMO 2024

Business Wire BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data for TEVIMBRA (tislelizumab) at the European Society of Medical Oncology 2024...\n more…

BeiGene Launches Employee Stock Purchase Offering

TipRanks Financial Blog BeiGene Ltd (HK:6160) has released an update. BeiGene Ltd. has announced a new offering period for its 2018 Employee Share Purchase Plan (ESPP), running from Septem...\n more…

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu Sells 5,556 Shares

Ticker Report BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) COO Xiaobin Wu sold 5,556 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of...\n more…